248 related articles for article (PubMed ID: 25108651)
1. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease.
Odendahl M; Grigoleit GU; Bönig H; Neuenhahn M; Albrecht J; Anderl F; Germeroth L; Schmitz M; Bornhäuser M; Einsele H; Seifried E; Busch DH; Tonn T
Cytotherapy; 2014 Sep; 16(9):1245-56. PubMed ID: 25108651
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood.
Beloki L; Ciaurriz M; Mansilla C; Zabalza A; Perez-Valderrama E; Samuel ER; Lowdell MW; Ramirez N; Olavarria E
J Transl Med; 2015 May; 13():165. PubMed ID: 25990023
[TBL] [Abstract][Full Text] [Related]
3. Selection of adenovirus-specific and Epstein-Barr virus-specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)-compliant conditions.
Freimüller C; Stemberger J; Artwohl M; Germeroth L; Witt V; Fischer G; Tischer S; Eiz-Vesper B; Knippertz I; Dörrie J; Schaft N; Lion T; Fritsch G; Geyeregger R
Cytotherapy; 2015 Jul; 17(7):989-1007. PubMed ID: 25866178
[TBL] [Abstract][Full Text] [Related]
4. The simultaneous isolation of multiple high and low frequent T-cell populations from donor peripheral blood mononuclear cells using the major histocompatibility complex I-Streptamer isolation technology.
Roex MCJ; Hageman L; Heemskerk MT; Veld SAJ; van Liempt E; Kester MGD; Germeroth L; Stemberger C; Falkenburg JHF; Jedema I
Cytotherapy; 2018 Apr; 20(4):543-555. PubMed ID: 29449085
[TBL] [Abstract][Full Text] [Related]
5. Manufacturing of highly functional and specific T cells for adoptive immunotherapy against virus from granulocyte colony-stimulating factor-mobilized donors.
Beloki L; Ramírez N; Olavarría E; Samuel ER; Lowdell MW
Cytotherapy; 2014 Oct; 16(10):1390-408. PubMed ID: 24954783
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.
Clancy LE; Blyth E; Simms RM; Micklethwaite KP; Ma CK; Burgess JS; Antonenas V; Shaw PJ; Gottlieb DJ
Biol Blood Marrow Transplant; 2013 May; 19(5):725-34. PubMed ID: 23380344
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
Koehl U; Dirkwinkel E; Koenig M; Erben S; Soerensen J; Bader P; Doerr HW; Preiser W; Weissinger E; Klingebiel T; Martin H; Lehrnbecher T
Klin Padiatr; 2008; 220(6):348-52. PubMed ID: 18949669
[TBL] [Abstract][Full Text] [Related]
8. Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines.
Peggs KS; Verfuerth S; Pizzey A; Khan N; Guiver M; Moss PA; Mackinnon S
Lancet; 2003 Oct; 362(9393):1375-7. PubMed ID: 14585640
[TBL] [Abstract][Full Text] [Related]
9. Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT.
Neuenhahn M; Albrecht J; Odendahl M; Schlott F; Dössinger G; Schiemann M; Lakshmipathi S; Martin K; Bunjes D; Harsdorf S; Weissinger EM; Menzel H; Verbeek M; Uharek L; Kröger N; Wagner E; Kobbe G; Schroeder T; Schmitt M; Held G; Herr W; Germeroth L; Bonig H; Tonn T; Einsele H; Busch DH; Grigoleit GU
Leukemia; 2017 Oct; 31(10):2161-2171. PubMed ID: 28090089
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous generation of multivirus-specific and regulatory T cells for adoptive immunotherapy.
Lugthart G; Albon SJ; Ricciardelli I; Kester MG; Meij P; Lankester AC; Amrolia PJ
J Immunother; 2012 Jan; 35(1):42-53. PubMed ID: 22130159
[TBL] [Abstract][Full Text] [Related]
11. Expansion of cytomegalovirus pp65 and IE-1 specific cytotoxic T lymphocytes for cytomegalovirus-specific immunotherapy following allogeneic stem cell transplantation.
Bao L; Dunham K; Stamer M; Mulieri KM; Lucas KG
Biol Blood Marrow Transplant; 2008 Oct; 14(10):1156-1162. PubMed ID: 18804046
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of suitable target antigens and immunoassays for high-accuracy immune monitoring of cytomegalovirus and Epstein-Barr virus-specific T cells as targets of interest in immunotherapeutic approaches.
Tischer S; Dieks D; Sukdolak C; Bunse C; Figueiredo C; Immenschuh S; Borchers S; Stripecke R; Maecker-Kolhoff B; Blasczyk R; Eiz-Vesper B
J Immunol Methods; 2014 Jun; 408():101-13. PubMed ID: 24877879
[TBL] [Abstract][Full Text] [Related]
13. Infusion of cytomegalovirus specific cytotoxic T lymphocytes from a sero-negative donor can facilitate resolution of infection and immune reconstitution.
Horn B; Bao L; Dunham K; Stamer M; Adler S; Cowan M; Lucas K
Pediatr Infect Dis J; 2009 Jan; 28(1):65-7. PubMed ID: 19034064
[TBL] [Abstract][Full Text] [Related]
14. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers.
Szmania S; Galloway A; Bruorton M; Musk P; Aubert G; Arthur A; Pyle H; Hensel N; Ta N; Lamb L; Dodi T; Madrigal A; Barrett J; Henslee-Downey J; van Rhee F
Blood; 2001 Aug; 98(3):505-12. PubMed ID: 11468143
[TBL] [Abstract][Full Text] [Related]
15. CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers.
Beloki L; Ciaurriz M; Mansilla C; Zabalza A; Perez-Valderrama E; Samuel ER; Lowdell MW; Ramirez N; Olavarria E
J Transl Med; 2014 Nov; 12():317. PubMed ID: 25406933
[TBL] [Abstract][Full Text] [Related]
16. HLA tetramers and anti-CMV immune responses: from epitope to immunotherapy.
Chen FE; Aubert G; Travers P; Dodi IA; Madrigal JA
Cytotherapy; 2002; 4(1):41-8. PubMed ID: 11953040
[TBL] [Abstract][Full Text] [Related]
17. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
[TBL] [Abstract][Full Text] [Related]
18. Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes.
Watanabe N; Kamachi Y; Koyama N; Hama A; Liang J; Nakamura Y; Yamamoto T; Isomura M; Kudo K; Kuzushima K; Kojima S
Cytotherapy; 2004; 6(5):514-22. PubMed ID: 15512918
[TBL] [Abstract][Full Text] [Related]
19. Rapid, large-scale generation of highly pure cytomegalovirus-specific cytotoxic T cells for adoptive immunotherapy.
Foster AE; Gottlieb DJ; Marangolo M; Bartlett A; Li YC; Barton GW; Romagnoli JA; Bradstock KF
J Hematother Stem Cell Res; 2003 Feb; 12(1):93-105. PubMed ID: 12662440
[TBL] [Abstract][Full Text] [Related]
20. Alloreactive cytotoxic CD4+ responses elicited by cytomegalovirus-infected endothelial cells: role of MHC class I antigens.
Weinberg A; Zhang L; Hayward AR
Viral Immunol; 2000; 13(1):37-47. PubMed ID: 10733167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
